Company Filing History:
Years Active: 2023
Title: Inventor Markus Liebscher: Pioneering Targeted Compounds for Medical Applications
Introduction
Markus Liebscher, based in Halle/Saale, Germany, is an innovative inventor recognized for his significant contribution to the field of targeted compounds. His expertise has led to the development of groundbreaking solutions that have the potential to enhance medical treatments and diagnostics.
Latest Patents
Liebscher holds a patent titled "Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker." This invention focuses on targeted compounds designed for the site-specific coupling of chemical moieties. The invention features a targeted compound comprised of at least one targeting domain capable of binding to a specific target, accompanied by a linking moiety made up of up to 80 amino acids, with a preference for alanine, proline, and serine. Additionally, it includes a coupling site consisting of cysteine or a cysteine-rich peptide motif. The linking moiety connects the targeting domain with a coupling site, allowing the development of fusion proteins with ubiquitin muteins, known as Affilin®, for various medical applications, particularly in the treatment or diagnosis of diseases.
Career Highlights
Markus Liebscher is associated with Navigo Proteins GmbH, where he contributes his expertise to advance the company’s research and development efforts. His innovative work is pivotal in creating novel compounds that can significantly impact the biopharmaceutical landscape.
Collaborations
While working at Navigo Proteins GmbH, Liebscher collaborates with talented individuals, including his coworkers Ulrich Haupts and Erik Fiedler. Together, they aim to push the boundaries of technology in the realm of targeted medical applications.
Conclusion
Markus Liebscher exemplifies the spirit of innovation within the scientific community. His patent and ongoing work contribute significantly to the field of medical science, showcasing the importance of targeted compounds in enhancing therapeutic approaches. Through his contributions and collaborations, he continues to inspire future advancements in medical research and applications.